公开(公告)号：US12054549B2

公开(公告)日：2024-08-06

申请号：US18050817

申请日：2022-10-28

申请人： Merck Patent GmbH

发明人： Ilhan Celik ,  Eike Staub ,  Miriam Urban ,  Sabine Raab-Westphal ,  Eileen Samy ,  Andrew Bender ,  Georgianna Varrone ,  Yin Wu ,  Daigen Xu

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61P11/00 ,  A61P17/02 ,  C07K16/28 ,  C12Q3/00 ,  G01N33/543

CPC分类号： C07K16/2848 ,  A61K39/395 ,  A61P11/00 ,  A61P17/02 ,  C07K16/2839 ,  C12Q3/00 ,  G01N33/54366 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76

摘要： A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

公开(公告)号：US20240052040A1

公开(公告)日：2024-02-15

申请号：US18136803

申请日：2023-04-19

申请人： Momenta Pharmaceuticals, Inc.

发明人： Birgit C. Schultes ,  Chia Lin Chu ,  Laura Rutitzky ,  Lynn Zhang ,  Leona E. Ling

IPC分类号： C07K16/28 ,  C07K16/00 ,  C07K16/06 ,  A61K39/395 ,  A61P7/00

CPC分类号： C07K16/2848 ,  C07K16/00 ,  C07K16/06 ,  A61K39/39516 ,  A61P7/00 ,  A61K2039/505

摘要： Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.

公开(公告)号：US11851492B2

公开(公告)日：2023-12-26

申请号：US17654801

申请日：2022-03-14

申请人： Merck Patent GmbH

发明人： Josef Straub ,  Eike Staub

IPC分类号： A61K38/09 ,  C07K16/28 ,  A61K39/395 ,  G01N33/574 ,  A61K45/06 ,  A61K39/00

CPC分类号： C07K16/2848 ,  A61K38/09 ,  A61K39/39558 ,  A61K45/06 ,  G01N33/57484 ,  G01N33/57488 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/94 ,  G01N2800/52 ,  A61K39/39558 ,  A61K2300/00 ,  A61K38/09 ,  A61K2300/00

摘要： A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan αv integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan αv integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.

公开(公告)号：US11661456B2

公开(公告)日：2023-05-30

申请号：US15985288

申请日：2018-05-21

申请人： Momenta Pharmaceuticals, Inc.

发明人： Birgit C. Schultes ,  Chia Lin Chu ,  Laura Rutitzky ,  Lynn Zhang ,  Leona E. Ling

IPC分类号： C12P21/08 ,  A61K39/00 ,  A61K38/36 ,  C07K16/28 ,  C07K16/00 ,  C07K16/06 ,  A61K39/395 ,  A61P7/00

CPC分类号： C07K16/2848 ,  A61K39/39516 ,  A61P7/00 ,  C07K16/00 ,  C07K16/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/41

摘要： Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.

公开(公告)号：US09750709B2

公开(公告)日：2017-09-05

申请号：US14185010

申请日：2014-02-20

申请人： NanoPharmaceuticals LLC

发明人： Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

IPC分类号： A61K31/198 ,  A61K47/48 ,  C07K16/28 ,  A61K9/51 ,  A61K9/00 ,  A61K31/35 ,  A61K49/00 ,  A61K49/08 ,  A61K49/10 ,  A61K49/12 ,  A61K51/04 ,  A61K51/06 ,  A61K31/192 ,  A61K31/195 ,  A61K31/4365 ,  A61K31/60 ,  A61K31/7076 ,  A61K31/727 ,  A61K31/65 ,  A61K39/44

CPC分类号： A61K31/198 ,  A61K9/0048 ,  A61K9/5153 ,  A61K31/192 ,  A61K31/195 ,  A61K31/4365 ,  A61K31/60 ,  A61K31/65 ,  A61K31/7076 ,  A61K31/727 ,  A61K39/44 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K47/68 ,  A61K47/6801 ,  A61K47/6811 ,  A61K47/6937 ,  A61K47/6939 ,  A61K49/0008 ,  A61K49/085 ,  A61K49/10 ,  A61K49/12 ,  A61K51/0402 ,  A61K51/0497 ,  A61K51/065 ,  C07K16/2848 ,  C07K2317/76 ,  Y10T428/2982

摘要： Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

公开(公告)号：US20170240638A1

公开(公告)日：2017-08-24

申请号：US15435425

申请日：2017-02-17

申请人： Maine Medical Center Research Institute

发明人： Peter C. Brooks ,  Jennifer M. Caron

IPC分类号： C07K16/28 ,  A61K38/39 ,  C07K16/30 ,  C07K16/18

CPC分类号： C07K16/2848 ,  A61K38/39 ,  A61K45/06 ,  C07K16/18 ,  C07K16/2818 ,  C07K16/2827

摘要： The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.

公开(公告)号：US20170218070A1

公开(公告)日：2017-08-03

申请号：US15401971

申请日：2017-01-09

申请人： Merck Patent GmbH

发明人： Axel Hoffmann ,  Heinrich Lannert ,  Klaus Brischwein ,  Frederic Christian Pipp ,  Juergen Reindl ,  Karin Groll ,  Michael Zuehlsdorf ,  Otmar Pfaff ,  Sabine Raab ,  Ulrike Dau ,  Benoit Destenaves

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2839 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2848 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76

摘要： The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.

公开(公告)号：US09567389B2

公开(公告)日：2017-02-14

申请号：US13781917

申请日：2013-03-01

申请人： MedImmune, LLC

发明人： Changshou Gao ,  Herren Wu

IPC分类号： C07K16/00 ,  C07K16/28 ,  C07K16/22 ,  C12N15/10

CPC分类号： C07K16/00 ,  C07K16/005 ,  C07K16/22 ,  C07K16/2842 ,  C07K16/2848 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/30 ,  C12N15/1037

摘要： The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.

摘要翻译： 本发明涉及编码当在细胞中表达时在细胞膜上显示的抗体文库或抗体片段的病毒载体。 本发明提供了包含病毒载体核酸的细胞和筛选具有所需特征的抗体或抗体片段的文库的方法。

公开(公告)号：US20160215053A1

公开(公告)日：2016-07-28

申请号：US14915590

申请日：2014-08-27

申请人： Gábor Firneisz ,  Ralf Jesenofsky ,  Matthias Löhr

发明人： Gábor Firneisz ,  Ralf Jesenofsky ,  Matthias Löhr

IPC分类号： C07K16/28 ,  A61K31/395 ,  A61K39/00 ,  A61K31/713

CPC分类号： C07K16/2866 ,  A61K31/395 ,  A61K31/713 ,  A61K39/0005 ,  A61K45/00 ,  A61K2039/53 ,  C07K14/4703 ,  C07K14/4743 ,  C07K14/522 ,  C07K16/2848 ,  C07K2317/21 ,  C07K2317/24

摘要： The subject of the invention is the application of CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the treatment of diabetes mellitus associated pancreatic cancer. The core of this invention is the discovery that the chronically increased glucose levels (chronic hyperglycemia) could may an important role in the development of the pancreatic cancer and that the development of the pancreatic cancer due to chronic hyperglycemia or an already developed pancreatic cancer may be prevented/inhibited/delayed by the inhibition of CXCL12 and IGFBP2. In addition the subject of the invention is the production of inhibitors for the application as a treatment of diabetes mellitus associated pancreatic cancer and pharmaceutical drugs containing the inhibitors.

摘要翻译： 本发明的主题是CXCL12（趋化因子（C-X-C motif）配体12）和IGFBP2抑制剂在治疗糖尿病相关胰腺癌中的应用。 本发明的核心是发现，长期增加的葡萄糖水平（慢性高血糖症）可能在胰腺癌的发展中起重要作用，并且由慢性高血糖或已经发展的胰腺癌引起的胰腺癌的发展可能是 通过抑制CXCL12和IGFBP2预防/抑制/延迟。 此外，本发明的主题是制备用于治疗糖尿病相关胰腺癌和含有抑制剂的药物的抑制剂。

公开(公告)号：US20150259421A1

公开(公告)日：2015-09-17

申请号：US14724115

申请日：2015-05-28

申请人： The University of North Carolina at Chapel Hill

发明人： David R. CLEMMONS ,  Laura A. Maile

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K47/48

CPC分类号： C07K16/2848 ,  A61K39/00 ,  A61K39/3955 ,  A61K47/6957 ,  C07K2317/34

摘要： The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

摘要翻译： 本发明提供αV＆bgr 3整联蛋白半胱氨酸环结构域激动剂和拮抗剂（包括肽激动剂及其拮抗剂及其类似物）及其使用方法。